These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 15894565)

  • 1. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.
    Rojo-Bustamante E; Abellanas MA; Clavero P; Thiolat ML; Li Q; Luquin MR; Bezard E; Aymerich MS
    Neurobiol Dis; 2018 Oct; 118():64-75. PubMed ID: 29936234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
    Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
    Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
    Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
    FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
    Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
    Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective 5-HT
    Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
    Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
    Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Bourque M; Grégoire L; Di Paolo T
    Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
    Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
    Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
    Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.